Table 3.
Change in general self-efficacy (GSE) from baseline and at the 3- and 6-month follow-ups.
| Follow-up | Control (n=112) | ITTa (n=110)b | PPc (n=76)d | ||||||||||||
|
|
|
Value | ORe (95% CI) | P value | Value | OR (95% CI) | P value | ||||||||
| 3 months | |||||||||||||||
|
|
Change in GSE score, mean (SD) | −0.568 (4.6) | 0.544 (4.0) | 2.261 to 0.038d | .06 | 0.941 (4.4) | −2.842 to −0.174d | .03f | |||||||
|
|
Improvement ≥5 points, n (%) | 10 (8.9) | 15 (14) | 1.663 (0.712 to 3.884) | .24 | 14 (19.2) | 2.420 (1.011 to 5.792) | .047f | |||||||
| 6 months | |||||||||||||||
|
|
Change in GSE score, mean (SD) | −0.397 (4.5) | 0.127 (4.3) | −1.689 to 0.642d | .38 | 0.384 (4.4) | −2.103 to 0.542d | .25 | |||||||
|
|
Improvement ≥5 points, n (%) | 13 (11.6) | 16 (15) | 1.339 (0.611 to 2.936) | .47 | 13 (17.8) | 1.650 (0.717 to 3.795) | .24 | |||||||
aITT: intention-to-treat.
b3 missing values (no general self-efficacy score at baseline).
cPP: per-protocol.
dOnly 95% CI shown as the statistical test (Student t test) does not generate odds ratio.
eOR: odds ratio.
fSignificant at P<.05.